Journal of Headache and Pain

Papers
(The H4-Index of Journal of Headache and Pain is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019346
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates228
Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) stud138
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update129
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy126
A prospective real-world analysis of erenumab in refractory chronic migraine122
European headache federation consensus on the definition of resistant and refractory migraine118
Headache characteristics in COVID-19 pandemic-a survey study104
Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study96
Migraine and neuroinflammation: the inflammasome perspective94
Migraine and sleep disorders: a systematic review91
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience87
Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study83
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)80
The fifth cranial nerve in headaches76
Comorbidities of primary headache disorders: a literature review with meta-analysis76
Lasmiditan mechanism of action – review of a selective 5-HT1F agonist71
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study68
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence66
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs64
Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials63
From transformation to chronification of migraine: pathophysiological and clinical aspects60
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) stu58
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects56
Long COVID headache56
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace56
Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy53
Headache medication and the COVID-19 pandemic49
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism49
Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study48
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine47
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months45
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis43
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)43
Applying a biopsychosocial model to migraine: rationale and clinical implications42
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis39
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance37
0.18147110939026